Benzinga··Globe NewswireSCYNEXIS Expands Pipeline With $8M PXL-770 Acquisition, Eyes Rare Kidney Disease Market
SCYNEXIS completes acquisition of PXL-770 AMPK activator for ADPKD treatment. Deal includes $8M upfront, up to $188M milestones; Phase 2 study planned for late 2026.
GSKSCYXacquisitionclinical development